Skip to main content

Oncology Convention


Olympia London


 Medical Imaging ConventionCPD Member

Oncology Digital Series

Subpage Hero

Oncology Digital Series


Here at Oncology Convention, we continue to find ways to inform on the future of Oncology through informative and interactive sessions. 

Introducing ‘Oncology digital’ – bringing you the latest technology, products, and trends, straight to you virtually! Join us as we bring digital events to your screens, full of exciting and new interactive content, discussions, and practices.

Join us as we embark on interactive learning, and don’t forget to watch our previous events on demand for FREE.

Our Previous Digital Events:

Precision Oncology: Beyond Biomarkers

In the last years, Precision Oncology - finding the right treatment for each individual patient - has been the paradigm of cancer care. It has become a ubiquitous concept in conferences, literature and general media and we have been led to believe this is the standard of care. 

The goal has proven to be more elusive in real life, though. The widespread use of molecular profiling of tumors to identify targetable alterations has shown that: tumors with the same clinically actionable alterations have a high variability in their responses to treatments, and only about one third of cancer patients have a known clinically actionable alteration 

Predicting drug response based on patient-derived 3D micro-tumors is emerging as a very important complement to molecular profiling in realizing the promise of Precision Oncology. IndiTreat® is the first such technology available for clinical use, initially focusing on colorectal cancer. 

More Information

Watch On-Demand

Proton beam therapy and hypofractionation in the treatment of cancer

In recent years, the demand for proton beam therapy – a specialised form of radiotherapy – has surged, positioning the UK as a key provider of this advanced treatment. In contrast to conventional radiotherapy using X-ray beams, proton beam therapy delivers beams of protons which are more targeted to reduce damage to peripheral tissue and organs. In its simplest form, its high precision and ability to stop the beam at a defined point means that it can dramatically reduce long-term side effects in some cases.

Dr Sarah Harris, Professor Roger Taylor, and John Pettingell from the Rutherford Cancer Centres provided an exciting and informative webinar on the evolving world of proton beam therapy.

More information

Watch on-demand